Potential use of chemoprotectants against the toxic effects of cyanotoxins: A review

• Autor(a) principal: Guzmán-Guillén R.
• Data de Publicação: 2017
• Outros Autores: Puerto M., Gutiérrez-Praena D., Prieto A.I., Pichardo S., Jos Á., Campos A., Vasconcelos V., Cameán A.M.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://hdl.handle.net/10216/120467
• topic: acetylcysteine; alpha tocopherol; amifostine; ascorbic acid; aurantiin; bacterial toxin; carnitine; cyanotoxin; cyclosporin A; cylindrospermopsin; cysteine; cytochalasin; epigallocatechin gallate; glutathione; melatonin; microcystin; osmotic agent; rifampicin; silymarin; sulforaphane; thioctic acid; trolox C; unclassified drug; heart failure; human; intoxication; liver hemorrhage; liver injury; nonhuman; oxidative stress; Review; tumor promotion

Cyanobacterial toxins, particularly microcystins (MCs) and cylindrospermopsin (CYN), are responsible for toxic effects in humans and wildlife. In order to counteract or prevent their toxicity, various strategies have been followed, such as the potential application of chemoprotectants. A review of the main substances evaluated for this aim, as well as the doses and their influence on cyanotoxin-induced toxicity, has been performed. A search of the literature shows that research on MCs is much more abundant than research on CYN. Among chemoprotectants, antioxidant compounds are the most extensively studied, probably because it is well known that oxidative stress is one of the toxic mechanisms common to both toxins. In this group, vitamin E seems to have the strongest protectant effect for both cyanotoxins. Transport inhibitors have also been studied in the case of MCs, as CYN cellular uptake is not yet fully elucidated. Further research is needed because systematic studies are lacking. Moreover, more realistic exposure scenarios, including cyanotoxin mixtures and the concomitant use of chemoprotectants, should be considered. © 2017 by the authors. Licensee MDPI, Basel, Switzerland.